Holen Sie sich die Stockscreener-App
27.76
0.62%
0.18
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits
Acadia Pharma GLP-1 Receptor Agonists Weight Management Diabetes Treatments *zLHGd49l0* - akhmetovfoundation.org
Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
Canaccord reiterates Acadia Pharmaceuticals stock rating on products By Investing.com - Investing.com India
ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains As Fundamentals Improve - Kalkine Media
The Technical Signals Behind (ACAD) That Institutions Follow - Stock Traders Daily
Did First-in-Class EU Approval for DAYBU Just Shift ACADIA Pharmaceuticals' (ACAD) Investment Narrative? - Sahm
Is ACADIA Pharmaceuticals (ACAD) Still Trading At A Discount As DAYBU Wins EU Approval? - Sahm
Deutsche Bank Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $38 - Moomoo
Deutsche Bank raises Acadia Pharma price target after EU approval of Daybu for Rett syndrome. - Pluang
Citi Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $40 - Moomoo
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $36 to $40 - Moomoo
Acadia Gets European Commission Nod for Daybu in Rett Syndrome - Eastern Progress
EC greenlights Acadia’s DAYBU for Rett Syndrome in Europe - pharmaphorum
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union - Via TT
ACADIA (ACAD) Close: Advances 1.05% to $29.34; Technical View: the Session Ends Within the Reported Technical Boundaries on the DayMarket Leader Picks - vinanet.vn
Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Great Lakes Advisors LLC Purchases New Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA (ACAD) Earnings Report: EPS Clears the Reported Estimate at the Close; Closing Reaction: The Stock Gains 1.09% in the Current UpdateSlow Growth Warning - vinanet.vn
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's What Happened - MarketBeat
BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $36 - Moomoo
Rice Hall James & Associates LLC Purchases Shares of 618,887 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
UBS Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $49 - Moomoo
Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD) - simplywall.st
UBS raises Acadia Pharmaceuticals stock price target on trial optimism By Investing.com - Investing.com Australia
ACAD Maintained by UBS -- Price Target Raised to $49.00 - GuruFocus
UBS raises Acadia Pharmaceuticals stock price target on trial optimism - Investing.com
GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming - MarketBeat
Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside - TradingView
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
STATE STREET CORP Adds to ACADIA Pharmaceuticals Inc (ACAD) Stak - GuruFocus
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
Canaccord reiterates Acadia Pharmaceuticals stock rating on products - Investing.com India
Royal Bank of Canada Trims Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline - Investing.com India
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data - MarketBeat
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline By Investing.com - Investing.com Nigeria
ACAD: DAYBUE STIX is quickly overtaking the original formulation as European launch preparations advance - TradingView
Acadia Pharmaceuticals stock hits 52-week high at $29.81 - Investing.com
Acadia Pharmaceuticals stock hits 52-week high at $29.81 By Investing.com - Investing.com Australia
ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains Fresh Market Attention - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $41.00 Price Target at Needham & Company LLC - MarketBeat
ACAD Maintains Buy Rating by Needham -- Price Target Raised to $41 - GuruFocus
Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript - AOL.com
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High: What Now? - Kalkine Media
Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating - Moomoo
Janus Henderson Group PLC Decreases Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week HighWhat's Next? - MarketBeat
Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says - Moomoo
Immunic appoints Elena Ridloff to board of directors - Yahoo Finance
ACAD Maintained by Citigroup -- Price Target Raised to $39.00 - GuruFocus
0.83%
2.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):